Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101
Robbins LLP, a shareholder rights law firm, is soliciting lead-plaintiff candidates for a securities class action against Aardvark Therapeutics (NASDAQ: AARD), with a deadline of October 13, 2026. The complaint alleges Aardvark misled investors about the safety and efficacy of lead drug candidate ARD-101, covering buyers in the February 13, 2025 IPO and anyone who purchased between February 13, 2025 and May 14, 2026.
Key figures
- Class period
- February 13, 2025 to May 14, 2026
- Lead plaintiff deadline
- October 13, 2026
- Stock drop mar 2026 pct
- -56.2%
- Stock drop may 2026 pct
- -32.1%
- Stock drop mar 2026 close
- 5.47
- Stock drop may 2026 close
- 4.57
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.